The study evaluates the impact of the ZyMōt™ ICSI microfluidic device on ICSI outcomes in couples with high sperm DNA fragmentation (DSB). Comparing two ICSI cycles in 28 couples—the first using conventional methods and the second using ZyMōt™ ICSI—significant improvements in clinical outcomes were observed. The biochemical pregnancy rate increased by 28.31%, the clinical pregnancy rate by 35.56%, and the live birth rate by 35.29%. Additionally, the miscarriage rate was reduced by 75%. The results suggest that sperm selection through microfluidics enhances embryo genetic integrity and reproductive outcomes.
